01
evidence-grounded, value-led strategy
indication-specific development, precedent and landscape intelligence combine to define what the milestone must establish to support differentiated value
the milestone's value, not just its completion
decision intelligence software for early neuropsychiatric drug development
paiva helps early-stage biotech teams define what their next milestone must establish, interactively evaluate development paths against evidence and resource constraints, and build a strategy they can defend as the evidence changes
01 / the challenge
a choice about dose, study design or development sequence changes more than the next readout — it affects what the program can prove, what other functions must deliver and which options remain open
start
milestone ambition
outcome
milestone value
choose a path that creates strategic value, uses resources effectively and opens the right opportunities for what comes next
02 / why paiva
paiva connects strategic objectives, evidence requirements and available resources to help teams evaluate development choices and maintain a coherent direction
01
indication-specific development, precedent and landscape intelligence combine to define what the milestone must establish to support differentiated value
the milestone's value, not just its completion
02
interactively model how development choices affect evidence, dependencies, resources and future options
understand what each choice establishes and commits you to
03
keep rationale, decisions and priorities connected as team assumptions, development outcomes and relevant external evidence change
know why your strategy holds and when to reconsider it
connect what matters, how you could get there and what changes along the way
03 / how it works
three connected stages turn program evidence and objectives into development choices, a full strategic assessment and a team-approved living strategy
what must the milestone establish to create differentiated value?
combine program evidence, indication intelligence, objectives and constraints to propose connected development, differentiation and investment theses
what makes the program worth advancing, meaningfully different and compelling to future investors?
which path best advances the milestone objectives?
interactively select, defer and sequence activities, then model their implications for evidence, dependencies, time, resources and future options
what can the team confidently stand behind?
select a candidate, conduct the full cross-functional strategic assessment, review the rationale and authorize a strategy with clear accountabilities
the living strategy
a strategy that outlives the meeting
the approved assessment stays linked to the relevant evidence, team assumptions, accountable decisions and next actions
source facts are never overwritten, team-entered assumptions are versioned with history, and paiva proposes revised priorities — substantive scientific interpretations are reassessed and reviewed, and only the team approves new commitments
assumptions updated
a change in financing or execution constraints prompts review of the committed path
landscape intelligence
new relevant competitor or regulatory evidence prompts review of affected theses and evidence needs
outcomes recorded
completed development work is logged, updates the evidence picture and informs proposed next priority actions
04 / the intelligence
paiva draws on indication-specific, source-linked clinical and development evidence, regulatory guidance, relevant precedents and multi-stakeholder and market landscapes to inform program-specific strategic decisions
paiva goes beyond surfacing intelligence — it connects relevant evidence to development choices, commitments and the decisions that follow
01 intelligence
published evidence · regulatory guidance · development precedents · clinical and competitive landscapes · stakeholder perspectives
02 program-specific judgment
what applies, what remains uncertain, what the evidence implies and which assumptions need testing
03 strategic direction
connected theses · requirements and dependencies · therapeutic value and investment logic · functional implications · accepted exposures · priority actions and decision gates
paiva assesses where each precedent applies, where the analogy breaks down, and what those distinctions mean for the development strategy
05 / built from experience
Sophia Lobo
founder, paiva
paiva was founded following four years in commercial strategy at Beckley Psytech, bringing experience across clinical evidence, therapeutic differentiation, patient perspectives and cross-functional development decisions into a specialist intelligence platform
Robert Conley, MD
neuroscience · clinical development · pharma leadership
former Chief Research & Development Officer, atai Beckley; former Chief Science Officer, Neuroscience, Eli Lilly & Co
Rebecca Verity
commercial strategy · pharma leadership
Chief Executive Officer, CaReMe Global; former Chief Commercial Officer, Beckley Psytech; former UK/Ireland commercial director, Johnson & Johnson
Frank Moscow
venture investment · company building
Oregon Venture Fund, Board of Advisors and Investment Committee
06 / contact
see how paiva brings evidence, development-path modeling and living strategic intelligence together for your program
one asset. one milestone. a decision you can defend
interested in a founding beta partnership?
founding beta partnership inquiryconfidential program information is discussed after scope, security and data-handling arrangements are agreed
or write to sophia@paivahq.com